Veradermics, Inc. (MANE)
116.05
+0.33
(+0.29%)
USD |
NYSE |
Sep 25, 12:20
Veradermics Enterprise Value : 4.015B for Sept. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 24, 2026 | 4.015B |
| September 23, 2026 | 4.018B |
| September 22, 2026 | 4.116B |
| September 21, 2026 | 3.893B |
| September 18, 2026 | 3.641B |
| September 17, 2026 | 3.721B |
| September 16, 2026 | 3.460B |
| September 15, 2026 | 3.521B |
| September 14, 2026 | 3.430B |
| September 11, 2026 | 3.316B |
| September 10, 2026 | 3.281B |
| September 09, 2026 | 3.345B |
| September 08, 2026 | 3.519B |
| September 04, 2026 | 3.296B |
| September 03, 2026 | 3.265B |
| September 02, 2026 | 3.294B |
| September 01, 2026 | 3.255B |
| August 31, 2026 | 3.292B |
| August 28, 2026 | 3.272B |
| August 27, 2026 | 3.434B |
| August 26, 2026 | 3.476B |
| August 25, 2026 | 3.457B |
| August 24, 2026 | 3.294B |
| August 21, 2026 | 3.476B |
| August 20, 2026 | 3.581B |
| Date | Value |
|---|---|
| August 19, 2026 | 3.828B |
| August 18, 2026 | 3.831B |
| August 17, 2026 | 3.702B |
| August 14, 2026 | 3.890B |
| August 13, 2026 | 3.818B |
| August 12, 2026 | 3.737B |
| August 11, 2026 | 3.732B |
| August 10, 2026 | 3.808B |
| August 07, 2026 | 3.960B |
| August 06, 2026 | 3.720B |
| August 05, 2026 | 3.832B |
| August 04, 2026 | 3.663B |
| August 03, 2026 | 3.438B |
| July 31, 2026 | 3.567B |
| July 30, 2026 | 3.552B |
| July 29, 2026 | 3.683B |
| July 28, 2026 | 3.841B |
| July 27, 2026 | 3.836B |
| July 24, 2026 | 3.756B |
| July 23, 2026 | 4.021B |
| July 22, 2026 | 3.770B |
| July 21, 2026 | 3.755B |
| July 20, 2026 | 3.611B |
| July 17, 2026 | 3.831B |
| July 16, 2026 | 3.602B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.159T |
| EyePoint, Inc. | 152.08M |
| Elanco Animal Health, Inc. | 14.55B |
| Amylyx Pharmaceuticals, Inc. | 3.111B |
| ANI Pharmaceuticals, Inc. | 1.935B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.50M |
| Total Expenses (Quarterly) | 23.50M |
| EPS Diluted (Quarterly) | -0.5625 |
| Earnings Yield | -2.24% |
| Normalized Earnings Yield | -2.244 |